Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor that is no longer authorized for marketing in the European Union [25], The Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) was a randomized, double-blind, placebo-controlled, event driven trial evaluating the safety and efficacy of SGLT2 inhibitors in patients with type 2 diabetes and recent hospitalization for worsening heart failure [14]. Here, SLC5A2 is linked to heart failure.